REPLIGEN CORP Deferred Tax Liabilities, Goodwill
REPLIGEN CORP (RGEN) had Deferred Tax Liabilities, Goodwill of $1.49 million as of 2020-12-31, per its 10-K filed 2021-02-24.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities
us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill · last filed 2021-02-24
- 2020-12-31: Deferred Tax Liabilities, Goodwill $1.49M.
- 2019-12-31: Deferred Tax Liabilities, Goodwill $1.29M.
- 2018-12-31: Deferred Tax Liabilities, Goodwill $1.08M.
- 2017-12-31: Deferred Tax Liabilities, Goodwill $807.00K; Deferred Tax Liabilities, Goodwill as first filed $33.17M.
| Period end | Deferred Tax Liabilities, Goodwill | Deferred Tax Liabilities, Goodwill as first filed |
|---|---|---|
| 2020-12-31 | $1.49M 10-K · filed 2021-02-24 | |
| 2019-12-31 | $1.29M 10-K · filed 2021-02-24 | |
| 2018-12-31 | $1.08M 10-K · filed 2020-02-26 | |
| 2017-12-31 | $807.00K 10-K · filed 2019-03-01 | $33.17M 10-K · filed 2018-02-22 |
| 2016-12-31 | $7.35M 10-K · filed 2018-02-22 | |
| 2015-12-31 | $501.00K 10-K · filed 2017-02-23 | |
| 2014-12-31 | $251.00K 10-K · filed 2016-02-25 | |
| 2013-12-31 | $44.00K 10-K · filed 2015-03-17 | |
| 2012-12-31 | $72.00K 10-K · filed 2014-03-14 | |
| 2011-12-31 | $48.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |